[HTML][HTML] Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice

Y Ishida, C Yamasaki, A Yanagi, Y Yoshizane… - The American journal of …, 2015 - Elsevier
Y Ishida, C Yamasaki, A Yanagi, Y Yoshizane, K Fujikawa, K Watashi, H Abe, T Wakita…
The American journal of pathology, 2015Elsevier
The molecular mechanisms underlying the hepatitis B virus (HBV) life cycle are poorly
understood because of the lack of appropriate in vitro infection models. Herein, we report a
highly effective in vitro HBV infection system using fresh human hepatocytes (HHs) isolated
from chimeric mice with humanized livers. After the inoculation of sera collected from HBV-
infected chimeric mice or patients to HHs, we measured levels of HBV DNA, mRNA,
covalently closed circular DNA, and viral protein expression in HHs. We investigated the …
The molecular mechanisms underlying the hepatitis B virus (HBV) life cycle are poorly understood because of the lack of appropriate in vitro infection models. Herein, we report a highly effective in vitro HBV infection system using fresh human hepatocytes (HHs) isolated from chimeric mice with humanized livers. After the inoculation of sera collected from HBV-infected chimeric mice or patients to HHs, we measured levels of HBV DNA, mRNA, covalently closed circular DNA, and viral protein expression in HHs. We investigated the neutralization activity of hepatitis B immune globulin and the effects of siRNA against sodium taurocholate–cotransporting polypeptide and clathrin heavy chain on HBV infection. We confirmed the expression of viral antigens in HHs and the presence of extracellular HBV DNA and hepatitis B surface antigen. The maximum infection rate was approximately 80%. Lamivudine and hepatitis B immune globulin treatment reduced HBV DNA levels in a dose-dependent manner. Knockdown of sodium taurocholate–cotransporting polypeptide and clathrin heavy chain significantly reduced the levels of hepatitis B surface antigen. Infection was successfully established using different donor HHs and inocula. Elevation of extracellular HBV DNA levels and the increase of HBV-positive HHs were blocked by continuous hepatitis B immune globulin treatment, indicating virus spread in this model. Chimeric mouse–derived HHs provide a robust in vitro infection model that can completely support the HBV life cycle.
Elsevier